Genomics

IDbyDNA to Present Three Seminars at World Microbe Forum

Retrieved on: 
Wednesday, June 16, 2021
Articles, Pharmaceuticals policy, Health sciences, Antimicrobial resistance, Evolutionary biology, Veterinary medicine, Life sciences, Microorganism, Antimicrobial, AMR, Genomics

SAN FRANCISCO , June 16, 2021 /PRNewswire-PRWeb/ -- Today, IDbyDNA , the company revolutionizing the use of metagenomics to improve health by decoding the unknown, is announcing its team's role at next week's World Microbe Forum, an online conference on cutting-edge, interdisciplinary microbial science.

Key Points: 
  • SAN FRANCISCO , June 16, 2021 /PRNewswire-PRWeb/ -- Today, IDbyDNA , the company revolutionizing the use of metagenomics to improve health by decoding the unknown, is announcing its team's role at next week's World Microbe Forum, an online conference on cutting-edge, interdisciplinary microbial science.
  • Explify RPIP also predicts resistance to 60 antimicrobials based on over 1,200 associated AMR markers supporting molecular surveillance for antimicrobial resistance.
  • The World Microbe Forum brings together international experts who will examine, discuss and envision solutions that science can offer to solve some of the gravest concerns confronting us today.
  • IDbyDNA is driving a paradigm shift in infectious disease testing by democratizing the power of genomics to improve health and decode the unknown.

Dovetail Genomics Announces New Capture Hi-C Targeted Enrichment Panels

Retrieved on: 
Wednesday, June 16, 2021
Branches of biology, Biology, Genetics, Genomics, Nuclear organization, Molecular biology, Omics, Chromosome conformation capture, Biotechnology, DNA sequencing, Functional genomics

Genome-wide Hi-C studies have been highly informativein defining thecritical relationship between chromosome architecture and gene expression.However, the sequencingdepthrequired can be asignificantbarrier tolarger studies.

Key Points: 
  • Genome-wide Hi-C studies have been highly informativein defining thecritical relationship between chromosome architecture and gene expression.However, the sequencingdepthrequired can be asignificantbarrier tolarger studies.
  • Dovetail'snew productsreduce the sequencing burden byover90%, enabling interactions between promoters and their regulatory elements to be studied at a fraction of the cost.
  • In addition, the targeted approach increasesthesensitivity and resolution of the assay.
  • Dovetail Genomics LLC is transforming genomics by making long-range information readily accessible to all.

Enterome's GeneMark-HM software highlighted as the most accurate microbiome gene prediction software in peer-reviewed publication NAR Genomics and Bioinformatics

Retrieved on: 
Wednesday, June 16, 2021
Branches of biology, Biology, Academic disciplines, Mathematical and theoretical biology, Genomics, Bioinformatics, GeneMark, Mark Borodovsky, Gene prediction, Microbiome, DNA sequencing, Metagenomics

Enterome worked in collaboration with Gene Probe Inc, a specialist in gene prediction software, to create GeneMark-HM.

Key Points: 
  • Enterome worked in collaboration with Gene Probe Inc, a specialist in gene prediction software, to create GeneMark-HM.
  • The publication showed that GeneMark-HM improves the accuracy of gene prediction in human microbiome metagenomic sequences in comparison with current state-of-art gene prediction tools.
  • Mark Borodovsky, CEO of Gene Probe Inc., said: "GeneMark-HM is the first of its kind gene prediction pipeline for the human microbiome.
  • Publication reference: GeneMark-HM: improving gene prediction in DNA sequences of human microbiome, A. Lomsadze and all, NAR Genomics and Bioinformatics, 2021 (1-11), doi: 10.1093/nargab/lqab047 - Link

Enterome's GeneMark-HM software highlighted as the most accurate microbiome gene prediction software in peer-reviewed publication NAR Genomics and Bioinformatics

Retrieved on: 
Wednesday, June 16, 2021
Branches of biology, Biology, Academic disciplines, Mathematical and theoretical biology, Genomics, Bioinformatics, GeneMark, Mark Borodovsky, Gene prediction, Microbiome, DNA sequencing, Metagenomics

Enterome worked in collaboration with Gene Probe Inc, a specialist in gene prediction software, to create GeneMark-HM.

Key Points: 
  • Enterome worked in collaboration with Gene Probe Inc, a specialist in gene prediction software, to create GeneMark-HM.
  • The publication showed that GeneMark-HM improves the accuracy of gene prediction in human microbiome metagenomic sequences in comparison with current state-of-art gene prediction tools.
  • Mark Borodovsky, CEO of Gene Probe Inc., said: "GeneMark-HM is the first of its kind gene prediction pipeline for the human microbiome.
  • Publication reference: GeneMark-HM: improving gene prediction in DNA sequences of human microbiome, A. Lomsadze and all, NAR Genomics and Bioinformatics, 2021 (1-11), doi: 10.1093/nargab/lqab047 - Link

AGBT Announces Inaugural Agricultural Meeting, Spring 2022

Retrieved on: 
Wednesday, June 16, 2021
Genomics, Agriculture, Academic disciplines

ST. LOUIS, Mo., June 16, 2021 /PRNewswire-PRWeb/ -- Advances in Genome Biology and Technology , (AGBT), recognized as a cornerstone in the genomics research community, just released dates for their inaugural agricultural conference, AGBT-Ag, taking place April 4-6, 2022, at the Loews Coronado Resort in Coronado, Ca.

Key Points: 
  • ST. LOUIS, Mo., June 16, 2021 /PRNewswire-PRWeb/ -- Advances in Genome Biology and Technology , (AGBT), recognized as a cornerstone in the genomics research community, just released dates for their inaugural agricultural conference, AGBT-Ag, taking place April 4-6, 2022, at the Loews Coronado Resort in Coronado, Ca.
  • This meeting will focus on the global impacts of breakthroughs made possible through innovations in agricultural genomics, which will improve productivity and sustainability in crop and livestock production.
  • AGBT-Ag fosters the needed dialogue and exchange of ideas to bring about the fourth agricultural revolution," Hearne says.
  • The Genome Partnership has been proudly organizing the Advances in Genome Biology and Technology (AGBT) meetings since 1999.

Phase Genomics Releases Platform for Discovering New Viruses in Microbiome Samples

Retrieved on: 
Tuesday, June 15, 2021
Biotechnology, Genetics, Health, Branches of biology, Bioinformatics, Phase Genomics, Biology, Genomics, Microbiome, Omics, Microbiomes, Microbiology, Human Microbiome Project, Computational genomics

Phase Genomics, the global leader in proximity-ligation based genomic solutions, today announced the launch of a new platform aimed at the discovery of viral genomes from complex microbiome samples.

Key Points: 
  • Phase Genomics, the global leader in proximity-ligation based genomic solutions, today announced the launch of a new platform aimed at the discovery of viral genomes from complex microbiome samples.
  • Phase Genomics has published the method and several datasets demonstrating the new capabilities of the ProxiMeta Metagenome Deconvolution Platform to bioRxiv .
  • The new method is integrated into Phase Genomics microbiome discovery platform, ProxiMeta , and is now available in conjunction with Phase Genomics reagent kits and sample prep services.
  • ABOUT PHASE GENOMICS Phase Genomics applies Hi-C and other proximity-ligation methods to enable chromosome-scale genome assembly, metagenomic deconvolution, as well as analysis of structural genomic variation and genome architecture.

Personal Genome Diagnostics Enters Collaborative Partnership with Clinical Molecular Diagnostics Laboratory of Major University Health System

Retrieved on: 
Tuesday, June 15, 2021
Biotechnology, Health, Genetics, Pharmaceutical, Oncology, Life sciences, Medical genetics, Biotechnology, Biology, Molecular diagnostics, Articles, Genomics

Personal Genome Diagnostics Inc. (PGDx), a leader in cancer genomics, today announced a collaborative partnership with the Duke University Health System (DUHS) Clinical Molecular Diagnostics Laboratory.

Key Points: 
  • Personal Genome Diagnostics Inc. (PGDx), a leader in cancer genomics, today announced a collaborative partnership with the Duke University Health System (DUHS) Clinical Molecular Diagnostics Laboratory.
  • As part of the collaborative partnership, PGDxs elio tissue complete will be the primary technology platform for the laboratorys clinical oncology genomic testing initiatives.
  • Through this partnership, PGDxs elio tissue complete assay will be integrated into DUHS Clinical Molecular Diagnostics Laboratory, demonstrating the value of a decentralized strategy that supports the democratization of genomic testing.
  • Personal Genome Diagnostics (PGDx) empowers the fight against cancer by unlocking actionable information from the genome.

The Impact Genome Project® and MassMutual Foundation Announce New Research Measuring Social Capital – particularly critical in post-pandemic America

Retrieved on: 
Monday, June 14, 2021
Public policy, Government, Finance, Labor, Professional services, Philanthropy, Consumer, Other Consumer, Foundation, Academic disciplines, Genomics, Jason Saul, Subfields of sociology, Social Capital, MassMutual, Genome project, Genome, The Impact Genome Project®, the MassMutual Foundation, THE IMPACT GENOME PROJECT®, THE MASSMUTUAL FOUNDATION

New research from The Impact Genome Project and the MassMutual Foundation finds marginalized populations face barriers to higher paying jobs, healthcare, and financial stability.

Key Points: 
  • New research from The Impact Genome Project and the MassMutual Foundation finds marginalized populations face barriers to higher paying jobs, healthcare, and financial stability.
  • Most recently, this includes identifying the need to better understand what it takes to build Social Capital and funding the Social Capital Genome.
  • Jason Saul, CEO of The Impact Genome Project and Dennis Duquette, President of the MassMutual Foundation, will convene for a live briefing, State of Impact: Social Capital, on Tuesday, June 29 at 3 p.m.
  • Read more about the Social Capital Genome in our White Paper: Cracking the Code on Social Capital, What Works & Why
    The Impact Genome Project uses precision data to solve the worlds most intractable social problems, including financial stability, employment, food security, housing, social capital and education.

Twist Bioscience Collaborates with Regeneron for Production of Genotyping by Sequencing Panel to Enable Diverse Genome-wide Screening

Retrieved on: 
Monday, June 14, 2021
Technology, Research, Genetics, Nanotechnology, Biotechnology, Health, Pharmaceutical, Other Science, Science, Branches of biology, Biology, Genomics, Molecular biology, Biotechnology, DNA, Population genetics, Single-nucleotide polymorphism, Genotyping, Genome-wide association study, Population genomics, Computational and Statistical Genetics

Twist will market the assay as the Twist Diversity SNP Panel , and will make the content available to researchers globally for their population genomics studies.

Key Points: 
  • Twist will market the assay as the Twist Diversity SNP Panel , and will make the content available to researchers globally for their population genomics studies.
  • Genome-wide association studies using genotyping microarrays have long been a critical tool in understanding how genetic variation impacts disease.
  • Underrepresentation of diverse populations in genomic analysis hinders the ability to fully understand disease cause and correlation and perpetuates inequality in patient care.
  • Addressing this gap, the Twist Diversity SNP panel is inclusive of approximately 1.4 million globally-representative genetic variations known as single-nucleotide polymorphisms (SNPs).

Bionano Genomics Appoints Richard Shippy, Former Affymetrix, Illumina and Cradle Executive, as its Chief Business Officer

Retrieved on: 
Monday, June 14, 2021
Genomics, Chief business officer, Leadership, Economy

SAN DIEGO, June 14, 2021 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) announced today that Richard Shippy has joined the company as its Chief Business Officer.

Key Points: 
  • SAN DIEGO, June 14, 2021 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) announced today that Richard Shippy has joined the company as its Chief Business Officer.
  • For Bionano, he will be responsible for leading product strategy, broadening its business into new markets and strategic expansion of its product and technology portfolios.
  • He co-founded and led commercial operations at Cradle Genomics, which is the leader in developing non-invasive prenatal tests based on analysis of intact cells.
  • Im grateful to Erik and the Bionano board for this unique opportunity, commented Rich Shippy, CBO of Bionano Genomics.